# Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype

> **NCT03718767** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 62 (actual)

## Conditions studied

- Glioma
- Glioblastoma
- High Grade Glioma
- Low Grade Glioma
- Malignant Glioma

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03718767
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-27
- **Primary completion:** 2024-11-05
- **Final completion:** 2026-11-30
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03718767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03718767, "Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03718767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*